Tempus AI, Inc. (BCBA:TEM)
Argentina
· Delayed Price · Currency is ARS | Market Cap | 13.32T |
| Revenue (ttm) | 1.85T |
| Net Income (ttm) | -355.63B |
| Shares Out | n/a |
| EPS (ttm) | -2,040.77 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 236 |
| Average Volume | 7,160 |
| Open | 6,500.00 |
| Previous Close | 6,670.00 |
| Day's Range | 6,365.00 - 6,500.00 |
| 52-Week Range | 5,160.00 - 13,350.00 |
| Beta | n/a |
| RSI | 51.19 |
| Earnings Date | May 5, 2026 |
About Tempus AI
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician’s desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sc... [Read more]
Financial Performance
In 2025, Tempus AI's revenue was $1.27 billion, an increase of 83.41% compared to the previous year's $693.40 million. Losses were -$245.03 million, -67.12% less than in 2024.
Financial numbers in USDNews
Tempus Named to TIME's 10 Most Influential Health and Life Science Companies of 2026
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company advancing precision medicine through the practical application of artificial intelligence, today announced it has been nam...
Tempus and USC Announce Strategic Collaboration to Accelerate AI-Driven Precision Medicine
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and the Keck School of Medicine of USC and Keck Medicine of USC,...
Tempus to Report First Quarter 2026 Financial Results on May 5
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the first q...
Tempus and Predicta Biosciences Announce Collaboration to Expand Life Sciences Access to Ultrasensitive Whole-Genome Sequencing Assay for Hematologic Malignancies and MRD Monitoring
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Predicta Biosciences, a precision oncology company developin...
Tempus AI Stock Jumps As Data Presentations Fuel Fresh AI Oncology Buzz
Tempus AI (NASDAQ:TEM) shares are up on Tuesday as the company announced the acceptance of 31 abstracts for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026.
Tempus AI Transcript: 25th Annual Needham Virtual Healthcare Conference
The session highlighted strong growth in diagnostics, especially oncology, and robust expansion in the data business with over $1.1 billion in TCV and new strategic collaborations. Ongoing investments in AI applications and platform tools, along with a disciplined capital allocation strategy, position the company for continued growth.
Tempus Announces 31 Abstracts for Presentation at the American Association for Cancer Research Annual Meeting 2026
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acceptance of 31 abstracts—including one ora...
Tempus Launches Automated “Active Follow-Up” Service to Support Guideline-Concordant Care
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of an automated clinical update servi...
Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced an expanded, multi-year collaboration with Gilea...
Tempus to Present at the 25th Annual Needham Virtual Healthcare Conference
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, will present at the 25th Annual Needham Virtual Healthcare Confe...
Tempus AI Stock Jumps, ALERT Trial Results Boost EHR Automation Buzz
Specifically, the study found a 40% relative increase in life-saving valve procedures and a 27% increase in multidisciplinary heart team evaluations within just 90 days.
Tempus and Medtronic Announce ALERT Trial Results Showing AI-Driven EHR Notifications Improve Treatment for Significant Valvular Heart Disease
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced results from the ALERT (Addressing undertreatmen...
Tempus and Blood Cancer United® Announce Collaboration to Develop One Of the Largest Pediatric Acute Myeloid Leukemia Real-World Data Registries
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Blood Cancer United® (formerly The Leukemia & Lymphoma Socie...
Why Tempus AI Stock Is Up Wednesday?
Tempus AI Inc (NASDAQ: TEM) shares are trading higher Wednesday morning after Needham analyst Ryan MacDonald reiterated a Buy rating on the stock and maintained a $75 price target.
Tempus Announces Study Highlighting the Role of Advanced Genomic Profiling Features in Identifying Clinically Actionable Findings
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the publication of a new study in JCO Precision ...
AI-Powered Tempus Inks New Multi-Year Merck Deal
Tempus AI Inc. (NASDAQ: TEM) on Tuesday inked a strategic collaboration agreement with Merck & Co. Inc. (NYSE: MRK) aimed at accelerating AI-driven precision medicine.
Tempus AI Transcript: Morgan Stanley Technology, Media & Telecom Conference 2026
The company leverages a unique, large-scale multimodal dataset and advanced AI to drive both diagnostics and data licensing businesses, with strategic pharma partnerships and high-margin growth. Foundation models and individualized predictions are set to transform precision medicine, with significant industry impact expected by 2026.
Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Merck, known as MSD outside of the United States and Canada,...
Tempus to Participate in the Morgan Stanley Technology, Media & Telecom Conference
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that it will participate in the Morgan Stanley T...
Tempus AI Stock Drops Despite Q4 Earnings Beat: Details
Tempus AI, Inc. (NASDAQ:TEM) shares fell in Tuesday's extended trading after the company released its fourth-quarter earnings report, despite beating estimates on the top and bottom lines.
Tempus AI Earnings Call Transcript: Q4 2025
Core business revenue grew over 33% in 2025, with diagnostics and data segments both exceeding expectations. 2026 guidance targets 25% revenue growth and $65M adjusted EBITDA, supported by strong bookings and high contract value. Oncology and data businesses are expected to grow 30%+.
Tempus Reports Fourth Quarter and Full Year 2025 Results
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarte...
Is TEM Stock A Buy At $60?
Tempus AI (NASDAQ: TEM) trades at a premium by traditional metrics, remains unprofitable on a GAAP basis, and has spent the past week benefiting from strong analyst optimism. So why might the stock st...
Tempus Announces Novel Pan-Cancer HRD-RNA Algorithm
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of its new HRD-RNA algorithm. This ne...
Tempus Announces Collaboration with Median Technologies to Integrate AI-Powered Lung Cancer Screening into the Pixel Platform
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a collaboration with Median Technologies (EPA: A...